Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC

作者：Brazel D, Nagasaka M · 发表于：Med (New York, N.Y.) · 年份：2024 · DOI：10.1016/j.medj.2024.06.012

Approximately 1 in 4 patients with NSCLC present with resectable disease. Although surgery is potentially curative, 30%-50% of patients relapse. Studies have shown that neoadjuvant, adjuvant, and perioperative chemoimmunotherapy improve outcomes. The Checkmate 77T trial explored if perioperative platinum-based chemotherapy plus nivolumab, surgical resection, then adjuvant nivolumab further improved outcomes including EFS.1.